Your session is about to expire
← Back to Search
Deprescribing Program for Dementia and Diabetes
N/A
Waitlist Available
Led By Medha Munshi, MD
Research Sponsored by Joslin Diabetes Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will check if a program can reduce the use of medications that cause low blood sugar in people with Alzheimer's and related diseases in long-term care facilities.
Who is the study for?
This trial is for clinical staff at long-term care facilities, including doctors, physician assistants, nurse practitioners, and clinical pharmacists. They must have participated in the STRIDE program aimed at educating on deprescribing diabetes medication for residents with Alzheimer's.
What is being tested?
The STRIDE educational program is being tested to see if it helps reduce the use of diabetes medications that carry a high risk of causing low blood sugar in elderly patients with dementia. The study will also evaluate how well the program is accepted and implemented by healthcare providers.
What are the potential side effects?
Since this trial focuses on an educational program rather than a medical intervention, there are no direct side effects from drugs or treatments. However, changes in prescribing practices could potentially affect patient health outcomes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use
Secondary study objectives
Acceptability of the STRIDE Educational Program
Appropriateness of the STRIDE Educational Program
Feasibility of the STRIDE Educational Program
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: STRIDE InterventionExperimental Treatment1 Intervention
Educational intervention for clinicians
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STRIDE
2019
N/A
~14200
Find a Location
Who is running the clinical trial?
Brown UniversityOTHER
466 Previous Clinical Trials
699,050 Total Patients Enrolled
19 Trials studying Dementia
208,004 Patients Enrolled for Dementia
Joslin Diabetes CenterLead Sponsor
97 Previous Clinical Trials
26,544 Total Patients Enrolled
Theoria MedicalUNKNOWN
1 Previous Clinical Trials
300 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- This criterion is not related to a clinical trial exclusion criteria. It appears to be related to the targeted providers for a specific program. If you need help with clinical trial exclusion criteria, please provide additional information.Staff who took part in the STRIDE program (Providers doing stakeholder exit interviews).
Research Study Groups:
This trial has the following groups:- Group 1: STRIDE Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger